Ontology highlight
ABSTRACT: Background
Biologic treatments impose a large financial burden on healthcare payers. Subcutaneous formulations of trastuzumab and rituximab offer administration cost savings relative to the intravenous products through reduced preparation and infusion times. However, intravenous biosimilars have the potential to offset administration costs through lower drug costs.Objective
The objective was to develop a budget impact model (BIM) from a payer's perspective for the EU-5 countries (UK, France, Germany, Spain, Italy) to demonstrate the economic impact of using intravenous trastuzumab and rituximab biosimilars.Methods
An incidence-based BIM was developed to estimate the net budget impact utilising epidemiology data from the literature, market research data on the use of
SUBMITTER: Jang M
PROVIDER: S-EPMC7803676 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature